Stifel lowered the firm’s price target on Hinge Health (HNGE) to $59 from $66 and keeps a Buy rating on the shares. Market volatility aside, the downdraft creates an interesting opportunity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Reaffirming Buy on Hinge Health: Strong Win Rates, Sustained Growth, and Limited Competitive Threats Support $65 Target
- Evercore ISI sees limited impact to Hinge from Sword Health-Kaia Health deal
- Darden upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Hinge Health initiated with a Buy at Freedom Capital
- Hinge Health: Strong Usage Momentum, Conservative Growth Expectations, and Competitive Moat Support Buy Rating